EGLN1 and leukemia: To corroborate the requirement for Phd2 in AML initiation using a distinct AML-driving oncogene, we combined the shPhd2 system with a DOX-inducible MLL-AF9 allele (iMLL-AF9)30, thus enabling activation of mixed-lineage-leukemia (MLL)-AF9 expression concurrently with Phd2 knockdown (and GFP reporter) upon DOX treatment (Fig. 1i and Extended Data Fig. 1d).